{"protocolSection":{"identificationModule":{"nctId":"NCT05395338","orgStudyIdInfo":{"id":"0135-0350"},"organization":{"fullName":"Boehringer Ingelheim","class":"INDUSTRY"},"briefTitle":"1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients","officialTitle":"1-year Clinical Outcomes After Intravenous Rt-PA for Chinese AIS Patients"},"statusModule":{"statusVerifiedDate":"2022-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-04-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-11-30","type":"ACTUAL"},"completionDateStruct":{"date":"2022-11-30","type":"ACTUAL"},"studyFirstSubmitDate":"2022-05-25","studyFirstSubmitQcDate":"2022-05-25","studyFirstPostDateStruct":{"date":"2022-05-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-12-22","lastUpdatePostDateStruct":{"date":"2022-12-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Boehringer Ingelheim","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The objective of the study is to find out the 1-year clinical outcomes among Acute Ischaemic Stroke (AIS) patients who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of symptom onset compared with those who arrived or were admitted to the hospital within 4.5 hours of symptom onset and did not receive any reperfusion treatment in a real-world clinical setting."},"conditionsModule":{"conditions":["Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":11700,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"IV rt-PA cohort","description":"Patients who received IV rt-PA within 4.5 hours of symptom onset","interventionNames":["Drug: rt-PA"]},{"label":"Non-reperfusion cohort","description":"Patients who arrived or were admitted to the hospital within4.5 hours of symptom onset and did not receive any reperfusion treatment"}],"interventions":[{"type":"DRUG","name":"rt-PA","description":"Recombinant Tissue Plasminogen Activator","armGroupLabels":["IV rt-PA cohort"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"All-cause mortality at 1 year (modified Rankin Scale (mRS) score =6)","description":"The modified Rankin Scale (mRS) is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.\n\nThe scale runs from 0-6, from 'perfect health without symptoms' to 'death'. 0 - No symptoms.\n\n1. - No significant disability. Able to carry out all usual activities, despite some symptoms.\n2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.\n3. - Moderate disability. Requires some help, but able to walk unassisted.\n4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.\n5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.\n6. - Dead.","timeFrame":"up to 1 year"}],"secondaryOutcomes":[{"measure":"mRS score 0-2 at 1 year","timeFrame":"up to 1 year"},{"measure":"mRS score 0-1 at 1 year","timeFrame":"up to 1 year"},{"measure":"mRS score 5-6 at 1 year","timeFrame":"up to 1 year"},{"measure":"Distribution of mRS score at 1 year","timeFrame":"up to 1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Patients registered in the ZSQCC platform from Jan 2017 to Mar 2020\n* â‰¥ 18 years of age\n* Diagnosed with AIS at admission\n* Arrived or admitted to the hospital within 4.5 hours of symptom onset\n* If treated with IV rt-PA: received IV rt-PA within 4.5 hours of symptom onset\n\nExclusion criteria:\n\n* Documented Intravenous Thrombolysis (IVT) contraindication except age to IV rt-PA treatment according to the Summary of Product Characteristics (SmPC)\n* Missing any one of the key data (age, gender, baseline National Institutes of Health Stroke Scale \\[NIHSS\\], time of symptom onset, time of hospital arrival or admission, IVT or not, time of IV rt-PA treatment)\n* Received thrombolysis agents other than rt-PA (urokinase, tenecteplase, recombinant plasminogen activator, prourokinase, streptokinase)\n* Received endovascular treatment\n* Received IV rt-PA after 4.5 hours of symptom onset","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"In this study, AIS patient data from 80 stroke centres in the Zhejiang Stroke Quality Control Centre (ZSQCC) platform from January 2017 to March 2020 will be used.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"Boehringer Ingelheim (China) Investment Co., ltd.","city":"Shanghai","zip":"200040","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Related Info","url":"https://www.mystudywindow.com"}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).\n\nFor more details refer to: https://www.mystudywindow.com/msw/datatransparency"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","submissionTracking":{"estimatedResultsFirstSubmitDate":"2023-11-28","submissionInfos":[{"releaseDate":"2023-11-28"}]}},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","relevance":"LOW"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}